Comparison 1. Melarsoprol monotherapy: Drug A vs Drug B.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death during treatment	3		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
1.1 Melarsoprol: graded (Angola regimen) vs fixed‐dose 10 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Melarsoprol: standard (3.6 mg) vs graded (26 days)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.3 Melarsoprol: standard (3.6 mg) vs incremental dose 10 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.4 Melarsoprol (standard 3.6 mg) vs nifurtimox (14 days)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.5 Melarsoprol: graded 26 days vs fixed 10 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Overall mortality	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2.1 Melarsoprol: graded (Angola regimen) vs fixed‐dose 10 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Melarsoprol: standard (3.6 mg) vs incremental dose 10 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Relapse during follow up	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.1 Melarsoprol: graded (Angola regimen) vs fixed‐dose 10 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Melarsoprol: standard (3.6 mg) vs incremental dose 10 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]